Market Analysis and Insights: Global Gastrointestinal Stromal Tumor (GIST) Drug Market
The global Gastrointestinal Stromal Tumor (GIST) Drug market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Gastrointestinal Stromal Tumor (GIST) Drug Scope and Market Size
The global Gastrointestinal Stromal Tumor (GIST) Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Gastrointestinal Stromal Tumor (GIST) Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Amcasertib
Anagrelide hydrochloride CR
APG-1351
Binimetinib
Others

Segment by Application
Clinic
Hospital
Others

The Gastrointestinal Stromal Tumor (GIST) Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Gastrointestinal Stromal Tumor (GIST) Drug market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Ariad Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Boston Biomedical, Inc.
Calithera Biosciences, Inc.
Chipscreen Biosciences Ltd
Deciphera Pharmaceuticals, LLC
F. Hoffmann-La Roche Ltd.
Horizon Pharma Plc
Immunicum AB
Jiangsu Hengrui Medicine Co., Ltd.
Kolltan Pharmaceuticals, Inc.
Natco Pharma Limited
Nerviano Medical Sciences S.r.l.
Novartis AG
Omeros Corporation